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In the acute phase of atopic dermatitis (AD), T-helper type 2 (Th2) cytokines characterize the inflammatory
response in the skin. IL-33 is a new tissue-derived cytokine, which is mainly expressed by cells of barrier tissues,
and is known to activate Th2 lymphocytes, mast cells, and eosinophils. IL-33 signals through a receptor complex
consisting of IL-33–specific receptor ST2 and a co-receptor IL-1RAcP. As IL-33 is known to promote Th2-type
immunity, we examined expression profiles of IL-33 and its receptor components in human AD skin, in the
murine model of AD, and in various cell models. We found increased expression of IL-33 and ST2 in AD skin
after allergen or staphylococcal enterotoxin B (SEB) exposure, as well as in the skin of 22-week-old filaggrin-
deficient mice. In addition, skin fibroblasts, HaCaT keratinocytes, primary macrophages, and HUVEC
endothelial cells efficiently produced IL-33 in response to the combined stimulation of tumor necrosis
factor-a and IFN-g, which was further enhanced by a mimetic of double-stranded RNA. Finally, the increased
expression of IL-33 and ST2 caused by irritant, allergen, or SEB challenge was suppressed by topical tacrolimus
treatment. These results suggest an important role for IL-33–ST2 interaction in AD and highlight the fact that
bacterial and viral infections may increase the production of IL-33.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin disease
affecting about 10 million people worldwide. A majority of
AD patients exhibit hyperproduction of total IgE, and most of
them have allergen-specific IgE in the sera. Classical T-helper
type 2 (Th2) cytokines such as IL-4, IL-5, and IL-13 are
expressed in the acute ezcematous lesions, whereas in
chronic lesions IFN-g–producing Th1 cells are dominant
(Bieber, 2010). In addition to classical Th2 cytokines, new
tissue-derived cytokines such as TSLP and IL-33 have
been suggested to have a significant role in AD (Kinoshita
et al., 2009; Smith, 2009). In the skin lesion, signals from
barrier disruption, allergens, and microbial colonization are
integrated and transmitted to diverse immune cells, which
initiate and maintain the skin inflammation (Carmi-Levy
et al., 2011). Patients with AD are particularly suscep-
tible to Staphylococcus aureus infections, partly because of
impaired expression of endogenous antimicrobial peptides
and defective stratum corneum barrier (Ong et al., 2002;
Nomura et al., 2003). Besides microbial skin infections,
patients with AD are susceptible to infection of certain viruses
(Wollenberg et al., 2003) due to disturbed skin barrier
function.
IL-33 (IL-1F11) is a recently described cytokine that
belongs to the IL-1 family and is linked to Th2-type immune
responses. IL-33 is expressed by cells of barrier tissues (e.g.,
skin, gut, and lung) and is known to activate naive and Th2
lymphocytes, mast cells, and eosinophils to produce Th2-
type cytokines (Schmitz et al., 2005; Liew et al., 2010).
However, IL-33 is not produced by Th2 cells, and its
signaling pathway distinguishes from classical Th2 cytokines.
IL-33 signals through a membrane-bound IL-33–specific
receptor ST2 (also known as IL1RL1, T1, DER4, and Fit-1)
and IL-1 receptor accessory protein (IL1-RAcP), which serves
as a shared co-receptor. The ST2 gene encodes at least three
isoforms of ST2 proteins: ST2L, a transmembrane form, the
soluble ST2, a secreted form that can serve as a decoy
receptor of IL-33, and a variant ST2 (Liew et al., 2010).
Membrane-bound expression of ST2 is highest on mast cells
(Moritz et al., 1998; Allakhverdi et al., 2007), Th2 cells
(Xu et al., 1998), and eosinophils (Cherry et al., 2008), which
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are critical cells in AD. IL-33 receptor complex is activated
when IL-33 binds to ST2 and IL-1RAcP, and recruits the
adaptor molecule MyD88 and IL-1R–-associated kinase IRAK.
Activated receptor complex induces activation of signaling
proteins, including transcription factor NF-kB and the
mitogen-activated protein kinase pathway (Schmitz et al.,
2005; Kurowska-Stolarska et al., 2008).
In the present study, we explored the expression of IL-33,
ST2, and IL-1RAcP in human AD skin, in the murine model
of AD and in various cell models. We show increased
expression of IL-33 and ST2 in AD skin after allergen or
staphylococcal enterotoxin B (SEB) exposure, and efficient
production of IL-33 by skin fibroblasts, HaCaT keratinocytes,
primary macrophages, and HUVEC endothelial cells in
response to the combined stimulation of tumor necrosis
factor (TNF)-a and IFN-g. In addition, 22-week-old filaggrin-
deficient mice spontaneously express IL-33 and ST2 in the
skin. Finally, the increased expression of IL-33 and ST2
caused by irritant, allergen, or SEB challenge is inhibited by
topical tacrolimus treatment.
RESULTS
ST2 and IL-1RAcP are upregulated in lesional skin of patients
with AD
Th2-type cytokines are produced in acute skin lesions of
patients with AD, and IL-33 is known to drive the production
of Th2-associated cytokines (Schmitz et al., 2005). To
investigate the expression of IL-33 and ST2 in AD, lesional
and nonlesional skin of patients with AD and skin from
healthy volunteers were investigated. We found a 2-fold
increase of ST2 and a 1.8-fold increase of IL-1RAcP mRNAs,
(Figure 1a) as well as a 3-fold increase of TNF-a and IL-13
mRNAs in lesional skin compared with nonlesional skin
(Figure 1b). IL-33 mRNA was also increased in lesional AD
skin, but the difference did not reach statistical significance.
IL-33 and ST2 were expressed at the same level in healthy
and nonlesional skin (Figure 1a). Immunohistochemical
staining revealed increased numbers of IL-33þ cells in
suprabasal keratinocytes and in endothelial cells of lesional
skin compared with nonlesional skin (Figure 1c–f). In
addition, increased numbers of ST2þ cells were found in
infiltrating inflammatory cells in the dermis and to some
extent also in the epidermis of the lesional AD skin (Figure
1g–j and Supplementary Figure S1a and b online). Isotype
control–stained AD skin did not show any positive staining
(Supplementary Figure S1c online).
Allergen exposure and filaggrin deficiency amplify the
expression of ST2 and IL-33 in mouse AD skin and in bone
marrow–derived mast cells
We investigated the expression of ST2 and IL-33 also in AD
mice, which were epicutaneously sensitized with ovalbumin
(OVA) allergen (modified from Wang et al., 2007). Skin
specimens were investigated after the first and third
sensitization weeks. A 3-fold increase of ST2 expression
was found after the third sensitization week compared with
the ST2 expression after the first sensitization week in OVA-
sensitized skin (Figure 2a). Similar to ST2 expression,
eosinophils and mast cells were increased in OVA-exposed
skin along with epicutaneous sensitization (Supplementary
Figure S2a online). Furthermore, mRNA levels of Th2-type
cytokines, IL-4 and IL-13, were upregulated (Supplementary
Figure S2c online) in accordance with ST2 expression. The
number of CD3þ and CD4þ cells was already increased
after 1 week of OVA exposure (Supplementary Figure S2b
online), together with the enhanced expression of IL-33 in the
OVA-sensitized skin (Figure 2a). Moreover, OVA-specific IgE
was upregulated in the serum of OVA-sensitized mice
(Supplementary Figure S3a online).
Filaggrin gene is closely linked to the increased risk to
develop AD, and it is essential for skin barrier function
(Palmer et al., 2006; Howell et al., 2007; Boguniewicz and
Leung, 2011). As IL-33 is a barrier tissue–derived cytokine,
we investigated IL-33 expression in filaggrin-deficient (ft/ft)
mice, which are known to develop AD-like skin lesions with
age, and start to produce IL-17, IL-23, IL-6, and IL-4 at the age
of 32 weeks (Oyoshi et al., 2009). We found that both IL-33
and ST2 were spontaneously upregulated in the skin of 22-
week-old mice, and a 10-fold increase and a 15-fold increase
of ST2 and IL-33 expressions were found, respectively, in
38-week-old ft/ft mice compared with 4-week-old ft/ft mice
(Figure 2b).
Increased numbers of mast cells have been described in
the lesional skin of patients with AD (Irani et al., 1989; Soter,
1989). In the present study, increased numbers of mast cells
were detected in the sensitized skin of AD mice (Supple-
mentary Figure S2a online). We also examined whether
cross-linking of IgE with specific allergen can stimulate bone
marrow–derived mast cells to produce both IL-33 and ST2.
Indeed, IgEþ allergen stimulation elicited enhanced expres-
sion of ST2 mRNA and vigorous production of IL-33 mRNA in
murine mast cells (Figure 2c).
House dust mite (HDM) and SEB induce IL-33 and ST2
expressions in AD skin
HDM is a common indoor allergen and an external triggering
factor in AD (Hammad et al., 2009). Therefore, ST2 and IL-33
mRNA levels were investigated in the skin of AD patients
with histories of HDM allergy after HDM atopy patch test.
We found that mRNA expression of IL-33 and ST2 was
upregulated after 6 and 2 hours of HDM exposure,
respectively (Figure 3a).
Furthermore, AD skin is frequently colonized with SEB-
producing strains of S. aureus that affects the degree of
disease severity (Michie and Davis, 1996; Breuer et al.,
2000). We investigated whether SEB can induce the
expression of IL-33 and ST2 in the skin of patients with AD.
IL-33 and ST2 were upregulated after SEB patch test, but it
was not an immediate reaction and increased after 24 hours
of exposure (Figure 3b).
We have earlier shown that dermal exposure to SEB
induces a mixed Th1- and Th2-type skin inflammation in
mice (Savinko et al., 2005). A 4.5-fold upregulation of ST2
and a 2-fold upregulation of IL-33 were found after repeated
topical SEB exposure in mouse skin compared with phos-
phate-buffered saline-treated skin (Figure 4a and b). Along
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with IL-33 and ST2, also TNF-a and IFN-g (Figure 4c and d),
as well as IL-4 and IL-13 (Figure 4e and f), mRNA levels were
increased in SEB-exposed skin. In addition, SEB-specific IgE
was similarly upregulated (Supplementary Figure S3c online).
Topical tacrolimus treatment decreases the expression of IL-33
and ST2 in mouse AD skin
Corticosteroids and calcineurin inhibitors are the most widely
used drugs in AD (Akdis et al., 2006). We examined whether
the topical treatment with corticosteroid or calcineurin
inhibitor has an effect on the mRNA expression of ST2 or
IL-33 in the OVA/SEB-exposed mouse skin. A 4-fold decrease
of ST2 (Figure 5a) and a 2-fold decrease of IL-33 (Figure 5b)
after tacrolimus treatment were observed, but no changes
were found after the treatment with class III corticosteroid
betamethasone-17-valerate compared with the OVA/SEB
group (Figure 5). Notably, increased expression of IL-33
was also found from vehicle-treated skin (vehicle¼ acetone/
phosphate-buffered saline—used as a solvent for betametha-
sone and tacrolimus), suggesting that mechanically (tape
stripping) and chemically (acetone solvent) induced skin
injury activates IL-33. Irritation-induced IL-33 expression was
not affected by tacrolimus or betamethasone, whereas ST2
expression was increased in the vehicle group after beta-
methasone treatment. IL-33 or ST2 was not detected in the
skin of untreated naive mice (Figure 5). However, tacrolimus
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Figure 1. ST2 and IL-1RAcP are increased in lesional skin of patients with atopic dermatitis (AD). (a) mRNA levels of ST2, IL-33, and IL-1RAcP and
(b) proinflammatory T-helper type (Th)2 and Th1 cytokines were analyzed by real-time reverse transcription-PCR in lesional and nonlesional skin of AD
patients and in the skin of healthy volunteers. Columns and error bars represent means±SEMs (n¼13–15). Immunohistological staining of IL-33 in
(c) nonlesional and (d) lesional skin of AD patients (n¼ 8). (e) Keratinocytes and (f) endothelial cells were IL-33þ . Immunohistological staining of ST2
in (g) nonlesional and (h) lesional skin of AD patients (n¼ 4). ST2þ cells were found from the (i) epidermis and (j) dermal inflammatory cell infiltrates.
*Po0.05; **Po0.01; and ***Po0.001. Bar¼200 mm in c, d, g, and h; 50mm in e, f, i, and j. RU, relative units; TNF, tumor necrosis factor.
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treatment increased OVA-specific IgE levels in mouse serum
(Supplementary Figure S3b online), whereas IL-33 and ST2
mRNA levels were downregulated (Figure 5).
Human dermal fibroblasts, HaCaT keratinocytes, macrophages,
and HUVEC endothelial cells produce IL-33 after stimulation
with the combination of TNF-a and IFN-c
Keratinocytes and fibroblasts are major structural cells of the
skin and likely have an important role in the pathogenesis of
AD. In addition, skin-infiltrating macrophages and endothe-
lial cells are important in the inflammatory response
associated with AD. We examined the expression of IL-33
in primary dermal fibroblasts, primary macrophages, HaCaT
keratinocytes, and HUVEC endothelial cell lines at different
cytokine environments relevant for AD. Fibroblasts, HaCaT
keratinocytes, and HUVEC endothelial cells, which were
stimulated with the combination of TNF-a and IFN-g,
produced high levels of IL-33 mRNA after 18 hours of
exposure (Figure 6a, Supplementary Figure S4 online). The
expression of IL-33 in TNF-aþ IFN-g–stimulated macro-
phages and HaCaT keratinocytes peaked already at 2 and
6 hours (Figure 6a), but the expression was lower than in
primary fibroblasts. Moreover, IFN-g–stimulated fibroblasts
expressed low levels of IL-33 after 18 hours of exposure
(Figure 6a). TNF-a or IL-4 alone, or the combination of TNF-a
and IL-4, had no effect on IL-33 expression in fibroblasts or
HaCaT keratinocytes.
Patients with AD are susceptible to infection of certain
viruses. To mimic viral exposure in the skin, fibroblasts were
transfected with a mimetic of double-stranded RNA (dsRNA)
polyinosic-polycytidylic acid [poly(I:C)] for 3 and 6 hours
with or without cytokine stimulation (TNF-aþ IFN-g).
Poly(I:C)-transfected fibroblasts did not express IL-33
(Figure 6b). However, fibroblasts that were first stimulated
with TNF-aþ IFN-g for 18 hours, and subsequently trans-
fected with poly(I:C) for 3 and 6 hours, produced enhanced
levels of IL-33 compared with the levels without poly(I:C)
transfection (Figure 6b). IL-33 protein expression was con-
firmed by western blotting using fibroblast extracts. We found
full-length IL-33 protein (31 kDa) from fibroblasts, which
were stimulated with the combination of TNF-a and IFN-g
for 18 hours (Figure 6c). In addition, poly(I:C) transfection
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Figure 2. ST2 and IL-33 mRNA expressions in mouse atopic dermatitis (AD)
skin and activated mast cells. (a) ST2 and IL-33 expressions in mouse
ovalbumin (OVA)-sensitized skin after the first and third sensitization week
were analyzed by real-time reverse transcription-PCR, n¼8 mice per group,
*Po0.05, **Po0.01, and ***Po0.001. (b) ST2 and IL-33 were increased
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(c) ST2 and IL-33 expressions are shown in IgEþ allergen-stimulated bone
marrow–derived murine mast cells. The columns and the error bars represent
means±SEMs of three replications. PBS, phosphate-buffered saline;
RU, relative units.
ST2
HDM atopy patch test
ST2
SEB patch test
IL-33
HDM atopy patch test
IL-33
SEB patch test
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
* *3.0
2.5
2.0
*
*
1.5
1.0
0.5
Fo
ld
 c
ha
ng
e
Fo
ld
 c
ha
ng
e
3.0
2.5
2.0
1.5
1.0
0.5
2.5
2.0
1.5
1.0
0.5
20
15
10
5
0
0 2 6 48
Time (hours)
0 2 6 24
Time (hours)
0 2 6 24
Time (hours)
0 2 6 48
Time (hours)
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enhanced cytokine-induced IL-33 expression. Poly(I:C) trans-
fection alone had little effect on IL-33 protein expression
(Figure 6c).
DISCUSSION
IL-33 is a recently described cytokine that promotes Th2-type
immune responses. Recent data suggest an important role of
IL-33 during the development and exacerbation of allergic
asthma, but its role in allergic skin inflammation is poorly
known. However, genetic polymorphism within the ST2 gene
region has been previously reported to have a strong
association with AD (Shimizu et al., 2005). To better
understand the role of IL-33 in AD, we investigated
expression profiles of IL-33 and its receptor components in
patients with AD, in mouse models, and in various cell
models.
As IL-33 is known to promote Th2-type immunity, we
sought to examine expression profiles of IL-33 and its
receptor components in the skin of patients with AD. Our
results show elevated levels of ST2 and its co-receptor IL-
1RAcP expressions in lesional AD skin. Used primers detect
both the shorter and longer variant of ST2 gene, and therefore
it might be that also soluble ST2 is analyzed together with the
membrane-bound ST2 receptor. Furthermore, immunohisto-
chemical staining revealed increased numbers of IL-33þ cells
in suprabasal keratinocytes and in endothelial cells. ST2 was
found in dermal infiltrating cells and to some extent also in
epidermal cells. Our results revealed that IL-33 and its
receptors are increased in lesional skin of patients with AD,
and thus may contribute to the pathogenesis of the disease.
To investigate the kinetics of IL-33 and ST2 during the
development of the disease, we utilized the mouse model of
AD. Mice were epicutaneously sensitized with OVA and
investigated in the early phase of the disease, i.e., after the
first sensitization week, and in the more chronic phase, i.e.,
after the third sensitization week. ST2 expression was
progressively upregulated during the sensitization in parallel
with the recruitment of the eosinophils, mast cells, and
expression of Th2 cytokines. In contrast, IL-33 was already
induced in OVA-sensitized skin after the first sensitization
week, as well as in tape-stripped and acetone-treated vehicle
skin, whereas no IL-33 was found in the skin of untreated
naive mice. These results suggest that skin injury per se is
sufficient to elicit the expression of IL-33. This is also in line
with a finding by Dickel et al. (2010) who found upregulation
of IL-33 mRNA after tape stripping in human skin. AD is
clinically characterized by intense pruritus, which induces
scratching of the skin. Thus, mechanical trauma to the skin,
induced by the repeated scratching in AD patients, induces a
strong expression of IL-33, which together with the recruit-
ment of ST2-expressing cells (mast cells, eosinophils, and Th2
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cells) enhances IL-33–ST2 interaction and promotes the
production of Th2 cytokines.
Flaky tail (gene symbol ft) is a mutation in chromosome 3
within the mouse epidermal differentiation complex (Lane,
1972). Ft/ft mice lack filaggrin and express a truncated
profilaggrin instead of the normal high-molecular-weight
profilaggrin (Presland et al., 2000). A previous report showed
that 32-week-old ft/ft mice spontaneously develop eczema-
tous lesions (Oyoshi et al., 2009). We investigated ST2 and
IL-33 expression in the skin of 4-, 22-, and 38-week-old ft/ft
mice, and found that both IL-33 and ST2 were highly
upregulated in 38-week-old filaggrin-deficient mice. As
filaggrin-deficient mice have defects in skin barrier function,
it is evident that also environmental factors can easily
penetrate the skin barrier and influence the development of
AD-like lesions. We suggest that in ft/ft mice skin structural
cells respond to environmental factors and start to produce
cytokines related to innate immunity.
Allergens and bacterial toxins are known triggering factors
in AD. We demonstrate increased expression of IL-33 and
ST2 in AD skin exposed to a common indoor allergen, HDM,
or superantigen SEB. Similarly, topical exposure to SEB elicits
increased expression of IL-33 and ST2 in mouse AD skin. We
also find high levels of IL-33 in mast cells after IgE-mediated
activation with an allergen. This is in accordance with the
recent finding by Hsu et al. (2010) who found IL-33
expression in mast cells after IgE/antigen stimulation. Taken
together, IL-33–ST2 interaction is regulated by common
triggering factors in AD, which may be critical in the
development of the disease. To our knowledge, no earlier
reports are available demonstrating that external triggering
factors of AD, HDM, and SEB are potent inducers of IL-33
and its specific receptor in AD skin.
Current topical treatment possibilities for AD are cortico-
steroids and calcineurin inhibitors (Akdis et al., 2006). We
investigated how these treatment modalities affect the
expression of IL-33 and ST2 in the murine AD skin. IL-33
and ST2 were suppressed with a calcineurin inhibitor,
tacrolimus, in the OVA/SEB-sensitized murine skin. In
contrast, a corticosteroid, betamethasone-17-valerate,
slightly increased the expression of ST2, when it was used
together with the phosphate-buffered saline/acetone vehicle.
This was a betamethasone-specific phenomenon, and we did
not find upregulation of ST2 after tacrolimus treatment in the
vehicle group. This is in accordance with a previous study
with another corticosteroid, dexamethasone, which failed to
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Figure 6. IL-33 protein is produced by stimulated dermal fibroblasts, HaCaT keratinocytes, and primary macrophages. (a) Primary human dermal fibroblasts,
HaCaT keratinocytes, and macrophages express IL-33 mRNA after stimulation with both tumor necrosis factor (TNF)-a and IFN-g, and (b) poly(I:C) transfection
further increases IL-33 mRNA expression in fibroblasts. (c) Stimulated dermal fibroblast extracts were western blotted, and SYPRO Ruby staining of the
immunoblot confirmed equal loading and transfer of proteins from cell lysate samples. Culture medium was used as a control. RU, relative units.
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reduce the transcription of IL-33 in stimulated primary
airway smooth muscle cells (Prefontaine et al., 2009). We
have previously shown that both tacrolimus and beta-
methasone-17-valerate downregulate Th2- and Th1-type
cytokines. However, tacrolimus was more effective in
downregulating IFN-g levels in the sensitized mouse skin
(Lehto et al., 2010). As IFN-g (in combination with TNF-a)
is essential for upregulation of IL-33 (described below), this
phenomenon can explain why tacrolimus is superior to
suppress IL-33 expression in allergen/SEB-induced skin
inflammation.
We identified a cytokine milieu that is sufficient to
upregulate IL-33 in various cells. We show that the
combination of TNF-a and IFN-g is crucial to highly
upregulate IL-33 expression in primary dermal fibroblasts,
primary macrophages, and keratinocyte and endothelial cell
lines. In line with our results, a synergistic increase of IL-33
was demonstrated when airway smooth muscle cells were
stimulated with the combination of TNF and IFN-g (Pre-
fontaine et al., 2009). These results may reveal a mechanism
as to how topical SEB exposure increases IL-33 production.
As demonstrated in the present study, topical exposure to SEB
induces a strong expression of TNF-a and IFN-g in addition
to Th2 cytokines. Thus, SEB exposure may activate T cells
or antigen-presenting cells to produce IFN-g and TNF-a,
resulting in enhanced expression of IL-33 in fibroblasts and
keratinocytes. Moreover, it has been shown that both TNF-a
and IFN-g are increased in the whole blood of patients with
chronic AD compared with patients with acute AD (Vakirlis
et al., 2010).
In patients with AD, genetic predisposition for skin
barrier dysfunction and defects in innate and adaptive
immunity can lead to higher frequency of bacterial and viral
infections. Herpes simplex and Molluscum contagiosum are
the most common virus infections in patients with AD
(Wollenberg et al., 2011). Both are DNA viruses that
are known to produce dsRNA (Weber et al., 2006). In the
present study, we observed a weak induction of IL-33 in
fibroblasts that were treated with a mimetic of dsRNA. In line
with our finding, a recent study shows that human bronchial
epithelial cells do not produce IL-33 after dsRNA stimulation
alone (Chustz et al., 2011). However, we found that
fibroblasts that were stimulated with the combination of
TNF-a and IFN-g before dsRNA produced enhanced levels of
IL-33, suggesting that viral infections may aggravate the
production of IL-33 in certain disease conditions. Recently,
Hong et al. (2010) found a new splice variant of IL-33, and its
significance in different disease conditions should be further
investigated.
In conclusion, we demonstrate upregulation of IL-33 and
ST2 in the lesional AD skin by known triggering factors of
AD. In addition to allergen exposure, irritants, scratching, as
well as bacterial and viral infections, may increase the
transcription of IL-33. We also show that topical tacrolimus
treatment strongly suppresses the expression of IL-33 and ST2
in AD skin. These results recommend an important role for
IL-33–ST2 interaction in the pathogenesis and disease severity
of AD.
MATERIALS AND METHODS
Patients
Punch biopsies (6mm) were taken, after obtaining informed consent,
from either nonlesional or lesional skin of 15 patients with chronic
AD and from the skin of 13 healthy volunteers. AD patients were
identified according to the criteria defined by Hanifin and Rajka
(1980). AD patients with a history of HDM allergy underwent AD
patch testing as described previously (Darsow and Ring, 2000).
Patients were without topical medication (glucocorticosteroids,
antibiotics, tacrolimus) for 1 week and without systemic medication
for 4 weeks before taking skin biopsies. Patch tests are described in
Supplementary Materials and Methods online. Studies were
approved by the appropriate local ethics committees and conducted
according to the Declaration of Helsinki Principles.
Mice and sensitization
Female Balb/c mice (aged 6–8 weeks) were obtained from Scanbur
A/S (Karlslunde, Denmark), and filaggrin-deficient mice (flaky tail
ft/ft, ma/ma, double homozygous for the flaky tail, and matted
mutations) were purchased from Jackson Laboratory (Bar Harbor,
ME) and maintained under pathogen-free conditions. All animal
experiments were approved by the State Provincial Office of
Southern Finland. Sensitization protocols are described in Supple-
mentary Materials and Methods online.
Cell cultures
Primary human dermal fibroblasts isolated from adult skin were
purchased from Gibco (Paisley, UK) and cultured in Medium 106
according to the manufacturer’s instructions (Gibco). Human
immortalized HaCaT keratinocytes (Rintahaka et al., 2008) were
cultured in DMEM (Lonza, Verviers, Belgium) containing 10% fetal
bovine serum, 2mM Ultraglutamine1 (Lonza), and antibiotics.
Human primary macrophages were obtained from leukocyte-rich
buffy coats from healthy blood donors (Finnish Red Cross Blood
Transfusion Service, Helsinki, Finland). Monocytes were isolated
and differentiated as previously described (Pirhonen et al., 1999).
Bone marrow cells of C57BL/6 mice were cultured and identified as
previously described (Gombert et al., 2005). The cells were
identified as mast cells by May-Gru¨nwald–Giemsa staining and by
flow cytometric analysis of c-kit (499% of c-kitþ cells) and IgE
receptor (89% of the cells positive) expression. Stimulations are
described in Supplementary Materials and Methods online.
Quantitative real-time reverse transcription-PCR (Taqman)
analysis
Quantitative real-time reverse transcription-PCR analyses were
performed as previously described (Savinko et al., 2005; Lehto
et al., 2010). Briefly, skin biopsies were homogenized with Ultra-
Turrax T8 (IKA Labortechnik, Staufen, Germany) to TRIzol (Invitro-
gen Life Technologies, Karlsruhe, Germany). RNA was isolated and
extracted from stimulated cells, or from skin biopsies, according to
the TRIzol instructions.
cDNA synthesis and Taqman analysis are described in Supple-
mentary Materials and Methods online.
Immunohistochemistry
Paraffin-embedded tissue sections (4 mm) were stained with anti-
human IL-33 and ST2 antibodies. Staining protocol and antibody
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details are described in Supplementary Materials and Methods
online.
Western blotting
IL-33 protein was analyzed by western blot analysis using whole-cell
extract as previously described (Kankkunen et al., 2010). Blotting
conditions are described in Supplementary Materials and Methods
online.
Statistics
The data were expressed as means (±SEM), and differences between
means were analyzed with the Graph Pad Prism software using a
Student’s t-test with a two-tailed test of significance. A Mann–Whit-
ney U-test was used when variances were different between groups
for unpaired comparisons. Differences at Po0.05 were considered
to be statistically significant.
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